Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF +7.51%81 10-Year Share Buyback Ratio is -3.40 as of Jun. 2026. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $16.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 51.11% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Wuxi AppTec Co's current 10-Year Share Buyback Ratio was -3.40%.
WUXIF's 10-Year Share Buyback Ratio is ranked better than 51.11% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.6
vs WUXIF: -3.40
Wuxi AppTec Co (OTCPK:WUXIF) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Wuxi AppTec Co 10-Year Share Buyback Ratio Related Terms
WUXIF vs TMO, DHR, NTRA: 10-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co 10-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's 10-Year Share Buyback Ratio falls into.
Wuxi AppTec Co 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -3.40 mean?
Wuxi AppTec Co (WUXIF) has a 10-Year Share Buyback Ratio of -3.40 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #66 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 48.9%.
Is Wuxi AppTec Co's 10-Year Share Buyback Ratio too high?
Wuxi AppTec Co's current 10-Year Share Buyback Ratio is -3.40. Based on the distribution chart, Wuxi AppTec Co ranks #66 out of 135 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's 10-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #66 out of 135 companies for 10-Year Share Buyback Ratio. This puts Wuxi AppTec Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 10-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Wuxi AppTec Co and its competitors. Wuxi AppTec Co's current 10-Year Share Buyback Ratio is -3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $16.58, compared to a current price of $25.85 — trading 55.9% above its estimated fair value. The current 10-Year Share Buyback Ratio is -3.40. Wuxi AppTec Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current 10-Year Share Buyback Ratio is -3.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $25.85 is trading 55.9% above its estimated GF Value™ of $16.58.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
10-Year Share Buyback Ratio: -3.40
GF Value™: $16.58 vs. price of $25.85 (55.9% above fair value)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
